---
title: "QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations"
description: "Formulary evidence on QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AHFS | American Hospital Formulary Service |
| ASP | Average sales price |
| CGI-C | Clinician Global Impression of Change |
| CGI-S | Clinician Global Impression of Severity |
| CI | Confidence interval |
| EMA | European Medicines Agency |
| FDA | United States Food and Drug Administration |
| HRQoL | Health-related quality of life |
| ISSVA | International Society for the Study of Vascular Anomalies |
| ITT | Intent-to-treat |
| LM | Lymphatic malformation |
| LMC | Lymphatic malformation with a cutaneous component |
| LMF | Lymphatic Malformation Function |
| mLM | Microcystic lymphatic malformation |
| mLM-IGA | Microcystic Lymphatic Malformation Investigator Global Assessment |
| mLM-MCSS | Microcystic Lymphatic Malformation Multi-Component Static Scale |
| mTOR | Mammalian target of rapamycin |
| mTORC1 | Mammalian target of rapamycin complex 1 |
| mTORC2 | Mammalian target of rapamycin complex 2 |
| NCT | ClinicalTrials.gov study identifier |
| NDA | New Drug Application |
| PGI-C | Patient Global Impression of Change |
| PGI-S | Patient Global Impression of Severity |
| PI3K | Phosphatidylinositol 3-kinase |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| PNDS | Protocole national de diagnostic et de soins |
| SAE | Serious adverse event |
| SELVA | Phase 3 study of QTORIN rapamycin in microcystic lymphatic malformations |
| TEAE | Treatment-emergent adverse event |
| TRAE | Treatment-related adverse event |
| TSQM-9 | Treatment Satisfaction Questionnaire for Medication, nine-item version |
| WAC | Wholesale acquisition cost |

## Related pages
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations.md)
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Economic information and modeling report](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: References](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: prevalence by geography](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses.md)
